StreetInsider.com News Articles

Form 4 PMV Pharmaceuticals, For: Oct 01 Filed by: Eckler Matthew Joseph

Mon, 05 Oct 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20261005/27148923.html

Form 3 PMV Pharmaceuticals, For: Oct 01 Filed by: Eckler Matthew Joseph

Mon, 05 Oct 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20261005/27148659.html

Form 8-K PMV Pharmaceuticals, For: Oct 01

Mon, 05 Oct 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20261005/27146525.html

PMV Pharmaceuticals adds biotech investor to its board

Mon, 05 Oct 2026 08:00:27 -0400

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) has appointed Matt Eckler, Ph.D., to its Board of Directors, according to a company statement. Dr. Eckler is a Principal at Samsara BioCapital, where he leads the firm's public equity strategy.

Dr. Eckler has more than two decades of combined experience in healthcare investing and scientific research. Before joining Samsara BioCapital in 2025, he held investment roles at ArrowMark Partners and GMT Capital, and served as Vice President and Senior Biotech Analyst at RBC Capital Markets. Earlier in his career, he conducted research on the genetics of early brain development and circuit-level plasticity.

He holds a B.S.

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

Mon, 05 Oct 2026 08:00:00 -0400

Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research

Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027

PRINCETON, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced the appointment of Matt Eckler, Ph.D., to its Board

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

Mon, 05 Oct 2026 08:00:00 -0400

Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research

Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027

Form SCHEDULE 13G PMV Pharmaceuticals, Filed by: Samsara BioCapital, L.P.

Tue, 15 Sep 2026 18:44:00 -0400

si-local-file:///var/storage/secattach/20260915/27066091.html

H.C. Wainwright Reiterates Buy Rating on PMV Pharmaceuticals Inc. (PMVP)

Tue, 08 Sep 2026 07:39:22 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $5.00 price target on PMV Pharmaceuticals Inc. (NASDAQ: PMVP).

The analyst commented: "Earlier this week, PMV reported updated results for rezatapopt 2,000mg QD in heavily pretreated ovarian cancer (OC) patients harboring a TP53 Y220C mutation from the Phase 2 portion of the PYNNACLE trial (n=76; 4 median prior Rx; 96% platinum-resistant/refractory). According to the company’s press release and presentation, as of the May 14, 2026 data cutoff, the investigator-assessed ORR per RECIST v1.1 was 46% (35/76), including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses. Median

PMV Pharmaceuticals reports 46% response rate in ovarian cancer trial

Mon, 31 Aug 2026 16:02:32 -0400

PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) released updated interim data from the Phase 2 portion of its PYNNACLE clinical trial, showing a 46% overall response rate in ovarian cancer patients treated with its experimental drug rezatapopt.

The data, cut off as of May 14, 2026, covered 76 patients with platinum-resistant or refractory ovarian cancer carrying a TP53 Y220C mutation. Of those patients, 35 responded to treatment, including four confirmed complete responses, 29 confirmed partial responses, and two unconfirmed partial responses, per investigator assessment using RECIST version 1.1 criteria.

The median time to response was 1.3 months, and the median duration of response was

PMV Pharmaceuticals reports 46% response rate in ovarian cancer trial

Mon, 31 Aug 2026 16:02:32 -0400

The median time to response was 1.3 months, and the median duration of response was

PMV Pharmaceuticals reports 46% response rate in ovarian cancer trial

Mon, 31 Aug 2026 16:02:32 -0400

The median time to response was 1.3 months, and the median duration of response was

Form 10-Q PMV Pharmaceuticals, For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924840.html

Form 10-Q PMV Pharmaceuticals, For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924840.html

Form 8-K PMV Pharmaceuticals, For: Aug 14

Fri, 14 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26924812.html

Form 8-K PMV Pharmaceuticals, For: Aug 14

Fri, 14 Aug 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260814/26924812.html

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights